The goal is to bolster U.S. domestic production and protect jobs, with projected revenue gains; exemptions extend to certain partners while negotiations for near-zero duties are possible if they commit to building factories in the United States.

The Trump administration unveils a sweeping tariff package targeting patented drugs and their active ingredients not covered by direct-to-consumer deals, imposing a 100% tariff with effective dates set after a 120-day window for large drugmakers and 180 days for smaller firms.

Alongside drugs, revised tariffs on metal products cut some duties from 50% to 25% and carve out exemptions for materials with under 15% metal content.

An editor’s note emphasizes that updates are planned as more information becomes available.

Officials frame the measures as a means to strengthen domestic industry, jobs, and investment, though critics worry benefits have yet to materialize.

Reporting notes the story is developing and will be updated as new details emerge, with contributions acknowledged from ABC News staff.

The coverage includes ongoing live updates and related posts about the administration’s trade actions and broader economic measures.

Analysts warn that the policy could heighten protectionism and policy uncertainty, potentially shaping the industry in the longer term.

Smaller-company talks aim to provide policy certainty and avoid hard pricing, though participation scope and timelines remain unclear.

Consumer outcomes hang on government-industry coordination, investment pace, and balancing affordability with innovation in medicines.

The piece situates the tariffs within a broader political and legal context, including past actions and responses from lawmakers and stakeholders.

Regulators face safety and oversight questions as newer peptide-based therapies gain popularity online, creating challenges for clinicians and patients alike.